Table 2

Adjusted mean levels (95% CI) of cardiovascular risk factor by glucose tolerance status and treatment group at annual visits*

OGTT status
P for OGTT statusP for interaction
NGTIGTDiabetes
SBP (mmHg)
    ILS group119.0 (118.2–119.7)121.2 (120.4–121.9)123.6 (121.5–125.8)<0.0010.04
    MET group122.1 (121.3–123.0)123.0 (122.3–123.7)122.9 (121.4–124.3)0.17
    Placebo group121.9 (121.0–122.8)123.1 (122.3–123.8)124.5 (123.1–125.8)0.003
    P value for treatment<0.001<0.0010.29
DBP (mmHg)
    ILS group74.0 (73.5–74.5)74.9 (74.4–75.4)77.2 (75.7–78.7)<0.001<0.001
    MET group77.0 (76.4–77.6)76.9 (76.5–77.4)76.4 (75.4–77.4)0.55
    Placebo group76.4 (75.8–77.0)76.8 (76.4–77.3)78.6 (77.7–79.5)<0.001
    P value for treatment<0.001<0.0010.004
Triglycerides (mmol/l)
    ILS group1.46 (1.42–1.51)1.64 (1.59–1.68)1.73 (1.62–1.85)<0.0010.68
    MET group1.65 (1.60–1.70)1.79 (1.74–1.84)1.85 (1.73–1.96)<0.001
    Placebo group1.59 (1.53–1.65)1.80 (1.75–1.86)1.86 (1.78–1.95)<0.001
    P value for treatment<0.001<0.0010.20
LDL cholesterol (mmol/l)
    ILS group3.11 (3.07–3.15)3.15 (3.12–3.19)3.12 (3.04–3.20)0.130.23
    MET group3.13 (3.09–3.17)3.15 (3.11–3.18)3.11 (3.04–3.18)0.48
    Placebo group3.21 (3.17–3.26)3.19 (3.15–3.23)3.12 (3.06–3.18)0.05
    P value for treatment0.0010.210.98
HDL cholesterol (mmol/l)
    ILS group1.22 (1.21–1.23)1.20 (1.19–1.21)1.18 (1.15–1.20)0.0020.81
    MET group1.20 (1.19–1.22)1.19 (1.18–1.20)1.17 (1.15–1.19)0.02
    Placebo group1.19 (1.18–1.20)1.17 (1.16–1.18)1.15 (1.13–1.16)<0.001
    P value for treatment0.001<0.0010.08
LDL-PPD (Rf × 1,000)
    ILS group272 (271–273)268 (266–269)263 (260–266)<0.0010.58
    MET group267 (266–269)265 (263–266)260 (257–263)<0.001
    Placebo group267 (265–268)264 (262–265)261 (259–263)<0.001
    P value for treatment<0.001<0.0010.35
  • *Means and CIs were obtained from fixed-effects models, with an autoregressive covariance structure to account for within-person variability and further adjustment for baseline age, sex, race/ethnicity, year of assessment, baseline CVD risk factor, and any medications that may affect the CVD risk factor. P values represent comparisons among treatment groups for each glucose tolerance category and vice versa.

  • †The P value for interaction indicates whether the effect of the OGTT status differs by treatment group. RF, relative flotation.